Danish medical dermatology company LEO Pharma has divested a portfolio of four non-core medicines to German pharmaceutical firm Cheplapharm for €300m ($357m).
The deal is in line with LEO Pharma’s 2030 strategy to boost its focus on new solutions for medical dermatology.
Go deeper with GlobalData
One-Alpha, Locoid, Pimafucin and Zineryt are the divested products, which are included within bone disorders/nephrology, dermatology and gynecology areas.
Last year, the annual turnover of the four products was about €110m ($130.9m).
LEO Pharma president and CEO Catherine Mazzacco said: “The divestment is an important step to strategically aligning our portfolio and increasing our focus on innovation in medical dermatology.
“Patients will be well served by Cheplapharm and we are confident that the company will be the right owner for this portfolio of well-established brands going forward.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe deal subject to customary closing conditions, including regulatory approvals. It is expected to close by December this year.
After the completion of the transaction, LEO Pharma and Cheplapharm will work on a smooth transition of the products and business.
Cheplapharm CEO Sebastian Braun said: “We are delighted to seize this unique opportunity to acquire a sizeable portfolio of mature and well-known branded pharmaceuticals from LEO Pharma.
“The products make a great fit with our existing portfolio in a number of therapeutic areas, and not least, they are characterised by a strong brand legacy, on which we are looking forward to building and expanding our portfolio further.”
In December last year, Cheplapharm signed an agreement to acquire commercial rights for Seroquel and Seroquel XR in the US and Canada from AstraZeneca.
The terms of the agreement included $35m in upfront payment from Cheplapharm while AstraZeneca may also receive up to $6m in future sales-contingent payments.
